Lesson plan
NEtPhOH-THPI
NEtPhOH-THPI, also known as N′-(2-methoxyphenylethyl)-THPI, is a serotonin 5-HT 2 receptor agonist and possible serotonergic psychedelic of the tetrahydropyridinylindole (THPI) family related to psychedelic tryptamines. It is a cyclized tryptamine with an NBOMe-like substitution. The drug is a potent and high-efficacy partial agonist of the serotonin 5-HT 2A receptor. Its affinity (K i ) for the receptor was 8.58 nM and its and values were 20.7 nM (66.5%) for G q signaling and 58.4 nM (80.7%) for β-arrestin2 signaling. NEtPhOH-THPI is also a potent near-full agonist of the serotonin 5-HT 2B receptor ( = 7.94 nM; = 88.9%) and a lower-potency full agonist of the serotonin 5-HT 2C receptor ( = 263 nM; = 105.1%). It is a weak serotonin reuptake inhibitor ( = 1,288 nM) as well. NEtPhOH-THPI induced the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It produced the head-twitch response at a dose of 3 mg/kg in mice but not at a dose of 1 mg/kg or 10 mg/kg. The drug produced about half the maximal number of head twitches as LSD. The preclinical pharmacokinetics of NEtPhOH-THPI via intraperitoneal injection have been studied. NEtPhOH-THPI was first described in the scientific literature by Rongyan Li and colleagues by 2025. A close non-hallucinogenic pyrrolopyridine analogue with antidepressant-like effects in rodents was also reported.…
Article summary
NEtPhOH-THPI, also known as N′-(2-methoxyphenylethyl)-THPI, is a serotonin 5-HT 2 receptor agonist and possible serotonergic psychedelic of the tetrahydropyridinylindole (THPI) family related to psychedelic tryptamines. It is a cyclized tryptamine with an NBOMe-like substitution. The drug is a potent and high-efficacy partial agonist of the serotonin 5-HT 2A receptor. Its affinity (K i ) for the receptor was 8.58 nM and its and values were 20.7 nM (66.5%) for G q signaling and 58.4 nM (80.7%) for β-arrestin2 signaling. NEtPhOH-THPI is also a potent near-full agonist of the serotonin 5-HT 2B receptor ( = 7.94 nM; = 88.9%) and a lower-potency full agonist of the serotonin 5-HT 2C receptor ( = 263 nM; = 105.1%). It is a weak serotonin reuptake inhibitor ( = 1,288 nM) as well. NEtPhOH-THPI induced the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It produced the head-twitch response at a dose of 3 mg/kg in mice but not at a dose of 1 mg/kg or 10 mg/kg. The drug produced about half the maximal number of head twitches as LSD. The preclinical pharmacokinetics of NEtPhOH-THPI via intraperitoneal injection have been studied. NEtPhOH-THPI was first described in the scientific literature by Rongyan Li and colleagues by 2025. A close non-hallucinogenic pyrrolopyridine analogue with antidepressant-like effects in rodents was also reported.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.